CH7233163 is a non-covalent ATP-competitive EGFR- del19 /T790M/C797S inhibitor that can achieve potent inhibitory activity and mutation selection by exploiting multiple interactions with the αC helix conformation of EGFR, with antitumor activity, and can be used in studies related to non-small cell lung cancer (NSCLC).
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related EGFR/HER2 Products |
|---|
| Zongertinib
Zongertinib (BI 1810631) is a human HER2-selective tyrosine kinase inhibitor that covalently binds to both wild-type and mutated HER2 receptors, including exon 20 insertion mutations, whilst sparing EGFR signaling. Zongertinib has antitumor activity. |
| Inetetamab
Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab shows antitumor activities when used alone or together with tyrosine kinase inhibitors. |
| BBT-207
BBT-207 is a reversible, mutant-specific EGFR inhibitor with antitumor activity. |
| VRN-11
VRN-11 is an EGFR C797S inhibitor. |
| TRX-221
TRX-221 is an EGFR C797S inhibitor. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
